证券日报网讯 2月24日，万邦医药在互动平台回答投资者提问时表示，截至2026年2月13日，公司的股 东人数为8209户。 （文章来源：证券日报） ...

Core Viewpoint - Wanbang Medical (301520) reported that as of January 20, 2026, the number of its shareholders reached 8,504 [1] Summary by Relevant Categories Company Information - Wanbang Medical has a total of 8,504 shareholders as of the specified date [1]

Group 1 - The core point of the article is that Beilong Precision reported a total of 10,078 shareholders as of February 10 [2]

Core Viewpoint - Wanbang Medical (301520) reported that as of January 30, 2026, the number of shareholders reached 7,983 [1] Group 1 - The company is actively engaging with investors through interactive platforms [1] - The increase in shareholder numbers indicates growing interest in the company [1]

Core Viewpoint - Wanbang Pharmaceutical (301520.SZ) expects a significant decline in net profit attributable to shareholders for 2025, forecasting a range of 28.61 million to 42.16 million yuan, representing a decrease of 50.70% to 66.55% compared to the previous year [1] Group 1: Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between 7.45 million and 10.97 million yuan, reflecting a substantial decline of 80.33% to 86.65% year-on-year [1] - The company's revenue and gross margin from its generic drug business have experienced a decline due to intensified competition in the industry and fluctuations in customer demand [1]

Financial Projections - The company expects a net profit attributable to shareholders of between 28.61 million and 42.16 million yuan for 2025, representing a decline of 50.70% to 66.55% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be between 7.45 million and 10.97 million yuan, reflecting a decrease of 80.33% to 86.65% year-over-year[3] Performance Challenges - The decline in performance is attributed to intensified competition in the generic drug industry and fluctuations in customer demand, leading to a decrease in revenue scale and gross margin[5] Strategic Initiatives - The company is actively optimizing operational efficiency and enhancing its R&D system to strengthen resilience in a challenging market environment[6]

二、参与认购私募基金的进展情况 证券代码：301520 证券简称：万邦医药 公告编号：2026-002 安徽万邦医药科技股份有限公司 关于公司控制的合伙企业认购私募基金份额的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次投资概述 为进一步满足安徽万邦医药科技股份有限公司（以下简称"公司"）业务布 局及未来发展需要，更好地借助专业机构的专业力量及资源优势，整合各方资源， 提升公司的综合竞争力，由公司控制的合肥群象齐鸣企业管理合伙企业（有限合 伙）（以下简称"合肥群象"）于 2025 年 12 月 22 日与石河子市隆泰股权投资管 理企业（有限合伙）等各方签署了《嘉兴隆峰创业投资合伙企业(有限合伙)合伙 协议》及相关文件，合肥群象作为有限合伙人以自有资金认缴出资 1,000 万元， 参与认购嘉兴隆峰创业投资合伙企业(有限合伙)（以下简称"合伙企业"）的基 金份额，认缴比例为 12.987%。具体内容详见公司 2025 年 12 月 23 日于巨潮资 讯网（http://www.cninfo.com.cn）上披露的《关于公司控制的合伙企业认购私 ...

Group 1 - The core point of the article is that Beilong Precision reported a total of 10,162 shareholders as of January 20, 2026 [2]

Group 1 - The core point of the article is that Wanbang Pharmaceutical reported a total of 8,504 shareholders as of January 20, 2026 [2]

Group 1 - A total of 344 companies listed on the ChiNext board reported their latest shareholder numbers as of January 10, with 115 companies experiencing a decline in shareholder numbers compared to the previous period, and 8 companies seeing a decline of over 10% [1] - The company with the largest decline in shareholder numbers is Yidian Tianxia, which reported 71,862 shareholders, a decrease of 23.09% from December 31, while its stock price has increased by 100.79% since the concentration of shares [1] - Jiangfeng Electronics and Hengshuai Co., Ltd. also reported significant declines in shareholder numbers of 19.29% and 16.65%, respectively, with stock price increases of 37.84% and 24.58% since the concentration of shares [1] Group 2 - 25 companies on the ChiNext board have shown a continuous concentration of shares, with some experiencing a decline in shareholder numbers for more than three consecutive periods, and one company has seen a decline for seven consecutive periods [1] - Huari Co., Ltd. reported a continuous decrease in shareholder numbers for seven periods, with a cumulative decline of 33.32%, while Lingpai Technology and Wanbang Pharmaceutical also reported declines of 15.35% and 7.14%, respectively [2] - The average stock price increase for concentrated shares since January 1 is 9.38%, with notable increases from Yidian Tianxia, Jingce Electronics, and Zhida Mai, which rose by 100.79%, 58.34%, and 45.39%, respectively [2] Group 3 - Among the concentrated shares, four companies have announced their performance forecasts for the full year of 2025, with Fute Technology expected to have a net profit increase of 143.12% [3] - Hanyu Group follows with an expected net profit increase of 0.60 million [3]